There are are 4 planned TRIUMPH trials investigating retatrutide's efficacy in treating obesity and its complications: #type2diabetes #cardiovascular disease #osteoarthritis NEW Data drop at #ADA2023: Retatrutide, a triple agonist (GLP1, GIP, glucagon) lost an incredible 24.2% of their body weight, which amounts to 58 lbs
Key advantages include their dual benefit for both weight loss and type 2 diabetes management, along with favorable cardiovascular outcomes
GLP-1 agonists are already driving trend, more on the way The explosion in popularity of GLP-1s will not come as a surprise to those sponsoring pharmacy benefits
The combination of medication, expert guidance, and structured support helped Angelia lose weight
(After some digging, it appeared that the peptide would be shipped from a compounding pharmacy.) The screening included a dozen or so questions about my basic medical history (like if I had cardiovascular disease, cancer, allergies, or psychiatric illness)
In: TerjungR, editor
